Drug intelligence / Profile preview

NuCel

Development stage: Phase 4
Lead developer: Organogenesis
Modality: Adult Stem Cells → Stem Cell Therapies → Cell Therapies, Tissue Cells → Other Cell Types → Cell Therapies
Administration: Surgical Implantation, Intra-articular Injection, Intralesional Injection

Overview

NuCel is a minimally manipulated allograft amniotic stem cell product derived from human amnion and amniotic fluid. It is processed aseptically and intended for use as an allograft tissue in surgical and sports medicine applications. The product is developed by the company NuCel, which is part of the NuTech group. Its primary indication involves regenerative medicine, leveraging the properties of amniotic-derived cells to support tissue repair and healing[2][4].

Brand names: NuCel

Beyond the preview

Go deeper on NuCel.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on NuCel.

Explore the full profile